GINA does not cover life insurance: what whole genome buyers need to know
The federal law most people assume protects them from genetic discrimination has a gap that the marketing for most consumer whole genome sequencing kits does not advertise: the Genetic Information Nondiscrimination Act, commonly called GINA, covers health insurance and employment, and nothing else. Life insurance, disability insurance, and long-term care insurance are explicitly outside its scope. As more consumers are drawn in by services from Nucleus Genomics, Sequencing.com, and others and generate 30x whole genome sequences that include hundreds of clinically annotated variants, the question of what happens to that data in a life insurance context is worth asking before you swab. The gap is not new, but the number of people creating genomic data that could theoretically be used in life insurance underwriting has never been larger.
The National Human Genome Research Institute, the federal agency that maintains the authoritative public summary of GINA at genome.gov, states directly that the law "does not apply to other kinds of insurance like life or long-term care coverage." That gap is not an oversight or a loophole -- it is a deliberate feature of the 2008 legislation, which passed after years of advocacy but reached a compromise that excluded non-health insurance markets from its scope. Under GINA as written, a life insurer may ask whether you have undergone genetic testing, may request the results, and may factor those results into underwriting decisions. No federal rule currently bars that.
The American Society of Human Genetics filed formal comments with the National Conference of Insurance Legislators in February 2026, as NCOIL's Life Insurance and Financial Planning Committee worked on model legislation that states could adopt. The ASHG letter, available on the society's website and dated February 17, 2026, recommended that any model bill bar life insurers from requiring genetic testing -- including, as the letter specified, complete genomic sequencing -- as a condition of coverage, renewal, or pricing. The society argued that the current legal gap discourages people from getting tests that could benefit their health, out of concern that the results could be used against them in a life insurance application. No final NCOIL model had been adopted at the time this article was written.
State law offers uneven coverage. Many states have independently extended genetic nondiscrimination protections to life or disability insurance beyond what GINA requires, but the specifics vary widely. California's AB 1798, which was under Assembly consideration as of April 2026 according to its published bill analysis, would bar life and non-health disability insurers from using genetic information in underwriting, with a $1.5 million face-value threshold for certain large policies. Consumers in states without comparable statutes have no equivalent protection today.
For someone deciding whether to order a WGS kit, the practical exposure today is not obvious or immediate. Consumer genomics results typically sit in company apps rather than in medical records, and there is no documented pattern of life insurers mining consumer genomics databases in the way the theoretical framework would permit. But the data exists once you create it, and the legal framework governing its use in insurance is genuinely incomplete. GINA prevents a consumer WGS provider -- Nucleus Genomics, Sequencing.com, SelfDecode, or any other -- from sharing your results with a health insurer without your authorization. It does not prevent a life insurer from asking you at the time of application whether you have had genetic testing done, or from requesting your results as a condition of a large policy. How you answer, and whether your state's law restricts that question, depends on where you live. The National Human Genome Research Institute's genome.gov summarizes the federal scope; your state insurance commissioner's office is the place to check for state-specific rules. Neither step is difficult, and neither is something the kit marketing tends to suggest.